PHARMACYTE BIOTECH, INC. Impairment of Intangible Assets (Excluding Goodwill)
PHARMACYTE BIOTECH, INC. (PMCB) reported Impairment of Intangible Assets (Excluding Goodwill) of $1.55 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. impairment of intangible assets (excluding goodwill) for fiscal 2026 was $1.55M.
- PHARMACYTE BIOTECH, INC. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $2.00M.
- PHARMACYTE BIOTECH, INC. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|
| 2026-04-30 | $1.55M 10-K · filed 2026-07-29 |
| 2025-04-30 | $0.00 10-K · filed 2026-07-29 |
| 2024-04-30 | $2.00M 10-K · filed 2025-08-11 |
| 2023-04-30 | $0.00 10-K · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |